M Notes on the design of bioequivelence study: emtricitabine/tenofovir/efavirenz PDF Guideline/guidance
M Notes on the design of bioequivelence study: ethambutol/isoniazid (16 January 2018) PDF Guideline/guidance
M Notes on the design of bioequivelence study: ethambutol/isoniazid/pyrazinamide/rifampicin PDF Guideline/guidance
M Notes on the design of bioequivelence study: ethambutol/isoniazid/rifampicin PDF Guideline/guidance
M Notes on the design of bioequivelence study: isoniazid/pyrazinamide/rifampicin PDF Guideline/guidance
M Notification of a change(s) to the key information of a product approved by a stringent regulatory authority (SRA) (4 December 2015) DOCX Application form
M Notification of an outcome of the national registration provided by the participating company to WHO-PQT, Annex 7 DOCX Template
M Notification of outcomes of national registration procedure by the NRA, Appendix 3, Part C PDF Template
M One-third of antimalarial medicines tested in six African countries fail to meet international quality standards (issued 25 February 2011) PDF Information note
M Outline of the content of an annual report on the activities of a prequalified quality control laboratory (QCL) (4 June 2016) PDF Guideline/guidance
M Oxytocin injection - Clarification of stability data and storage statement requirements PDF Guideline/guidance
M PQT/MED reliance on the work of national regulatory agencies and regional regulatory systems – new pathways PDF Guideline/guidance